Correction to “Prophylactic evaluation of verubecestat on disease- and symptom-modifying effects in 5XFAD mice”

IF 6.8 Q1 CLINICAL NEUROLOGY

Alzheimer''s and Dementia: Translational Research and Clinical Interventions Pub Date : 2025-05-22 DOI:10.1002/trc2.70026

引用次数: 0

Abstract

Oblak AL, Cope ZA, Quinney SK, et al. Prophylactic evaluation of verubecestat on disease- and symptom-modifying effects in 5XFAD mice. Alzheimers Dement. 2022;8:e12317. doi: 10.1002/trc2.12317

In the submitted Supplementary Methods, we discovered a mistake where an image was duplicated in S1 and S2. This image is correctly labeled in S1, but the same image was accidentally included in S2. We have corrected this error in the attached file by replacing the image with the correct IBA1 immunohistochemistry image.

查看原文本刊更多论文

对“verubecestat对5XFAD小鼠疾病和症状改善的预防评价”的更正

Oblak AL, Cope ZA, Quinney SK，等。verubecestat对5XFAD小鼠疾病和症状改善作用的预防评价。阿尔茨海默病。2022;8:e12317。在提交的补充方法中，我们发现了S1和S2中重复图像的错误。此图像在S1中被正确标记，但在S2中意外包含了相同的图像。我们已经在附件中更正了这个错误，用正确的IBA1免疫组织化学图像替换了图像。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Alzheimer''s and Dementia: Translational Research and Clinical Interventions Medicine-Psychiatry and Mental Health

CiteScore

10.10

自引率

2.10%

发文量

134

审稿时长

10 weeks

期刊介绍： Alzheimer''s & Dementia: Translational Research & Clinical Interventions (TRCI) is a peer-reviewed, open access,journal from the Alzheimer''s Association®. The journal seeks to bridge the full scope of explorations between basic research on drug discovery and clinical studies, validating putative therapies for aging-related chronic brain conditions that affect cognition, motor functions, and other behavioral or clinical symptoms associated with all forms dementia and Alzheimer''s disease. The journal will publish findings from diverse domains of research and disciplines to accelerate the conversion of abstract facts into practical knowledge: specifically, to translate what is learned at the bench into bedside applications. The journal seeks to publish articles that go beyond a singular emphasis on either basic drug discovery research or clinical research. Rather, an important theme of articles will be the linkages between and among the various discrete steps in the complex continuum of therapy development. For rapid communication among a multidisciplinary research audience involving the range of therapeutic interventions, TRCI will consider only original contributions that include feature length research articles, systematic reviews, meta-analyses, brief reports, narrative reviews, commentaries, letters, perspectives, and research news that would advance wide range of interventions to ameliorate symptoms or alter the progression of chronic neurocognitive disorders such as dementia and Alzheimer''s disease. The journal will publish on topics related to medicine, geriatrics, neuroscience, neurophysiology, neurology, psychiatry, clinical psychology, bioinformatics, pharmaco-genetics, regulatory issues, health economics, pharmacoeconomics, and public health policy as these apply to preclinical and clinical research on therapeutics.